Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Beovu
|
| gptkbp:activities |
VEGF inhibitor
|
| gptkbp:appointed_by |
intravitreal injection
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:effective_date |
October 2019
FDA approved |
| https://www.w3.org/2000/01/rdf-schema#label |
brolucizumab injection
|
| gptkbp:indication |
treatment of diabetic macular edema
|
| gptkbp:ingredients |
gptkb:brolucizumab
C_22 H_28 N_6 O_5 S |
| gptkbp:is_used_for |
treatment of neovascular age-related macular degeneration
|
| gptkbp:manager |
intraocular
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:Beovu
|
| gptkbp:side_effect |
retinal detachment
eye pain intraocular inflammation vision changes cataract formation |
| gptkbp:storage |
refrigerated
|